tradingkey.logo
tradingkey.logo
Search

Amneal Pharmaceuticals Inc

AMRX
Add to Watchlist
17.310USD
+0.020+0.12%
Close 06/30, 16:00ETQuotes delayed by 15 min
5.52BMarket Cap
44.64P/E TTM

Amneal Pharmaceuticals Inc

17.310
+0.020+0.12%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+0.12%

5 Days

+7.45%

1 Month

+31.44%

6 Months

+34.08%

Year to Date

+37.38%

1 Year

+112.92%

Key Figures
17.300Open
17.490High
2.24MVolume
44.64P/E TTM
13.96P/E Dynamic
--Dividend TTM
0.70%Turnover Ratio
17.290Prev. Close
17.170Low
31.46MTurnover
LossP/E Static
-121.60P/B
0.00%Div Yield TTM
5.25%ROA
15.42052wk High
0.66Volume Ratio
-116.89MNet Profit
319.00MShares
0.3877EPS TTM
1.31Beta
-155.38%ROE
7.07052wk Low
1.85%Amplitude
44.31%Gross Margin
5.52BMarket Cap
17.72Reward/Risk
1.92%Risk Rate

Key Insights

Amneal Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amneal Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
32 / 157
Overall Ranking
85 / 4570
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Amneal Pharmaceuticals Inc Highlights

StrengthsRisks
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.12% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 44.59, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.64M shares, decreasing 13.73% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 21.70K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
17.250
Target Price
+0.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amneal Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Amneal Pharmaceuticals Inc Info

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Ticker SymbolAMRX
CompanyAmneal Pharmaceuticals Inc
CEOPatel (Chintu)
Websitehttps://amneal.com/

FAQs

What is the current price of Amneal Pharmaceuticals Inc (AMRX)?

The current price of Amneal Pharmaceuticals Inc (AMRX) is 17.29.

What is the symbol of Amneal Pharmaceuticals Inc?

The ticker symbol of Amneal Pharmaceuticals Inc is AMRX.

What is the 52-week high of Amneal Pharmaceuticals Inc?

The 52-week high of Amneal Pharmaceuticals Inc is 15.42.

What is the 52-week low of Amneal Pharmaceuticals Inc?

The 52-week low of Amneal Pharmaceuticals Inc is 7.07.

What is the market capitalization of Amneal Pharmaceuticals Inc?

The market capitalization of Amneal Pharmaceuticals Inc is 5.52B.

Is Amneal Pharmaceuticals Inc (AMRX) currently rated as Buy, Hold, or Sell?

According to analysts, Amneal Pharmaceuticals Inc (AMRX) has an overall rating of Buy, with a price target of 17.25.

What is the Earnings Per Share (EPS TTM) of Amneal Pharmaceuticals Inc (AMRX)?

The Earnings Per Share (EPS TTM) of Amneal Pharmaceuticals Inc (AMRX) is 0.23.
KeyAI